Multiple sclerosis

Half of MS patients discontinue medicinal cannabis

Almost half of patients who are initial responders to nabiximols oromucosal spray (Sativex) for spasticity in MS have discontinued the medicinal cannabis at 18 months, a European study shows. An Italian study of 1845 MS patients prescribed the treatment for moderate to severe spasticity resistant to other medications confirmed most patients (81.4%) had the requisite ...

Already a member?

Login to keep reading.

© 2022 the limbic